SUMMARY
Introduction
Familial hypercholesterolemia (FH) is the world's most common heritable disorder of lipid metabolism with the estimated prevalence in general population of 1:200-1:500 (Goldstein et al. 2001; Nordestgaard et al. 2013) . The phenotype of FH is characterized by cholesterol depositions in tissues and blood vessels of mutation carriers creating tendon xanthoma, xanthelasma and arcus lipoides corneae (Goldstein et al. 2001 ). Due to the increased deposition of cholesterol in blood vessels, the atherosclerosis process is accelerated, what leads to a significantly higher risk of premature cardiovascular diseases (CVD) (Goldstein et al. 2001; Khachadurian 1988) . Therefore, early clinical diagnosis confirmed by the DNA analysis and effective treatment is crucial to reduce the mortality and high risk of premature atherosclerosis complications (Vogt 2015) .
From the genetic point of view, the disease is caused by mutations in genes affecting the processing of LDL particles from circulation, resulting in an increase in both LDL cholesterol and total cholesterol, respectively. The most common cause of FH are mutations in the gene encoding LDL receptor (LDLR), followed by mutations in the gene for apolipoprotein B (APOB), and rarely mutations in the proprotein convertase subtilisin/kexin 9 gene (PCSK9) (Austin et al. 2004) . Currently, 1701 unique variants in the LDLR gene are reported (http://databases.lovd.nl/shared/genes/LDLR). Therefore, each country has its specific spectrum of LDLR mutations. In contrast to this, there are two very prevalent mutations, i.e. p.Arg3527Gln (in Europeans) and p.Arg3527Trp (in Asians) in APOB gene covering vast majority of the APOB mutation carriers (Tai et al. 1998) .
In this study we aimed to examine the genetic background of patients suspected on FH from Slovak nation-wide survey. before age of 65 years in the patient or first degree relative, and c. presence of xanthoma or arcus lipoides corneae in the patient/family relative. Patients with secondary cause of hypercholesterolemia (based on the information from the questionnaire) were excluded from the study. Samples of venous blood were collected for DNA analysis, and together with the Informed Consent form and the Questionnaire were transported to the DIABGENE laboratory.
Patients and methods

Study design and participants.
Molecular genetic analyses.
Genomic DNA was extracted from peripheral blood leukocytes using Whole Blood DNA Maxi Preparation Kit (BioTeke Corporation, China). DNA analysis was divided into three consecutive steps (finding a genetic cause of FH in one of them excluded patients from the oncoming DNA analyses).
1. APOB analysis. Real-time PCR (allelic discrimination) of the most common mutation p.Arg3527Gln in APOB gene was performed using TaqMan SNP Genotyping Assay ID: c_1026605_10, rs5742904 (Applied Biosystems, Germany) and analyzed using the fast Realtime PCR system 7900HT (ABI, Germany). Data were evaluated using the SDS v2.4 software.
2. Bidirectional sequencing of LDLR gene. Promoter region and all 18 coding exons and exon/intron boundaries of the LDLR gene were amplified by polymerase chain reaction (PCR) using previously described primers (Taylor et al. 2010; Chater et al. 2006; Tichy et al. 2012 ).
PCR products were sequenced using standard protocol on an ABI 3500 (Applied Biosystems, Warrington, UK) and were compared with the reference sequence NM_000527.4 using SeqScape software (version 2.1.1; Applied Biosystems, Warrington, UK signed an informed consent for the genotype and phenotype analyses.
Results
Genotypes of the patients with FH.
The APOB mutation p.Arg3527Gln was detected in 14 out of 235 probands (6%) and 2 family relatives out of 124. In the remaining probands, we have identified 89 (37.9%) with LDLR mutation (Table 1) . Out of their 122 family relatives 75 had an LDLR mutation. One of the positive probands was a compound heterozygote for two mutations in LDLR gene (p.Arg416Trp/p.Gly592Glu), this is the first case of genetically confirmed compound heterozygote FH patient in Slovakia.
The mutational spectrum in the LDLR gene consisted of 54 different mutations, from them 40
were substitutions, 9 small insertions and deletions and 5 large rearrangements (Table 1) . No regional mutational hot-spots were observed, but the most frequently detected mutation p.Gly592Glu, was found in 12 probands (13.5%) and 8 family relatives. Finder. In silico analyses of the novel LDLR mutations are displayed in the Table 2 . Neither of the novel mutations was present in more than 400 ethnically matched chromosomes.
Moreover, none of the mutations was present in the 1 000 Genomes Project, or in more than 6,500 individuals screened in NHLBI Exome Sequencing Project. The cosegregation of the novel variants with elevated LDL-C or TC levels in family pedigrees predicted their pathogenicity (data not shown).
In one proband a novel variant p.Asp170Glu in LDLR gene was identified. In silico analyses of this variant did not predict the pathogenicity, in addition this variant did not cosegregate with elevated LDL-C levels in proband's family.
Genotype-phenotype correlations. TC and LDL-C levels in probands with heterozygous LDLR mutation (LDLR+) were significantly higher compared to both APOB mutation unrelated carriers (p<0.05) and probands with no mutation detected in studied genes (APOB-/LDLR-) (p<0.0001). However there were no significant differences between APOB+ probands and APOB-/LDLR-probands in TC and LDL-C levels. No significant changes in HDL-C and TG levels were observed between particular groups (Table 3 ). In family relatives carrying the APOB or LDLR mutation, no significant differences in phenotype (i.e. total, LDL, HDL cholesterol, or triglycerides) compared to the probands were observed (data not shown). The compound heterozygous proband has manifested untreated TC level 15 mmol/l, had an evidence of tendon xanthoma and suffered from MI at the age of 48 years. (Table 3) .
Probands with tendon xanthomas suffered more frequently from CVD below the age of 65 years than probands without tendon xanthomas (26.9% vs. 5.8%; p<0.05).
Discussion
This is the first study assessing the molecular genetic background of autosomal dominant hypercholesterolemia due to LDLR gene mutations, including the first report of genetically confirmed compound heterozygote patient in Slovakia. Of the 235 probands we have identified 103 (43.8%) probands with mutation in one of the genes studied.
The most frequent mutation in APOB gene p.Arg3527Gln was identified in 14 probands (6.0%) and 2 family relatives out of 124. The frequency of the p.Arg3527Gln mutation in this study is in agreement with published data from neighboring countries (Czech republic 11.8%, Poland 6.6%, Austria 4.7% and Hungary 5.5%) (Tichy et al. 2012; Chmara et al. 2010; Widhalm et al. 2007; Kalina et al. 2001) and also in agreement with our previous study (9.7%) (Gasparovic et al. 2007 ).
In the LDLR gene, we have identified a mutation in 89 probands (37.9%) and 75 family relatives. The mutational spectrum revealed 54 different mutations including 9 novel variants.
For the clinical suspicion of FH, it is critical to assess whether the novel variant is pathogenic or not, therefore set of criteria need to be used for pathogenicity evaluation. The first criterion is the co-segregation of LDLR variant with clinical phenotype. The second criterion is based upon the in silico analyses. All variants were predicted as pathogenic (Table 2 ). In addition, one novel variant p.Asp170Glu was identified in one proband. This novel variant was predicted by Polyphen2 as benign and by SIFT/Provean as neutral. Moreover, the phenotypegenotype cosegregation in the family has not proven the pathogenicity, therefore we conclude that the variant p.Asp170Glu in the LDLR gene is a rare polymorphism.
From 54 different mutations, 40 mutations were substitutions, 9 small insertions (up to 100bp) and 5 large rearrangements (Table 1) . The identified mutations occurred in almost all exons except the exons 11, 15 and 18. Most frequently, mutations were detected in exon 4, which is the longest exon of the LDLR. Nevertheless, the broad range of mutation spectrum highlighted the importance of analyzing the whole gene during molecular diagnosis in order to identify all potential mutations.
In some populations only a few mutations of the LDLR due to the founder effect predominate, (Leitersdorf et al. 1993) and Finns (Koivisto et al. 1995; Aalto-Setala et al. 1989 ). On the other hand, the heterogeneous mutational spectrum of LDLR was published in most countries (Table 4) .
The most common mutation in Slovakia was p.Gly592Glu (13.5% of all LDLR positive probands), which is in agreement also with findings in the Czech Republic and Poland, where this mutation accounts for 19% and 22% Czech and Polish FH cases, respectively (Tichy et al. 2012; Chmara et al. 2010 ). The second most common mutation in this study p.Arg416Trp, is also the third most common mutation in the Czech Republic. In addition, the second most common mutation identified in Czech Republic p.Asp266Glu was also one of the most common mutations in Germany and Austria; however in Slovakia we found this mutation only in 3% of positive probands. These findings indicate similar mutational spectrum of the LDLR in the Central Europe region. On the contrary, the geographically distant countries show different mutation spectrum in comparison to the countries of Central Europe (Table 4 ).
In concordance with other studies, the probands with mutation in the LDLR gene have higher age-adjusted TC and LDL-C levels compared to APOB+ and APOB-/LDLR-probands (Tichy et al. 2012) ( Table 3 ). No significant difference was observed in HDL-C and TG levels between the three groups studied.
Concerning the TG levels, the data in literature are not consistent. No differences in TG levels were reported in large studies (Fouchier et al. 2005) . On the other hand, high levels of TG in LDLR-compared to LDLR+ patients were observed in other studies (van Aalst-Cohen et al.
2006
; Tichy et al. 2012) . In a previous study from Slovakia, APOB+ patients had significantly lower TG levels than other patients with clinical diagnosis of FH (Gasparovic et al. 2007 ). We cannot exclude that certain proportion of subjects with clinical diagnosis of FH in our previous study were in fact affected by familial combined hyperlipidemia (FCH) that in individual patients can manifest with similar phenotype as in FH. In absence of tendon xanthomas in a patient without sufficient family history of lipid phenotypes in relatives, it might be difficult to distinguish FH from FCH.
The most serious consequence of FH is the increased risk of cardiovascular disease. The occurrence of CVD in probands/relatives was between (37-42%) and the evidence of tendon xanthomas was highest in LDLR+, followed by APOB+ and the lowest occurrence was in APOB-/LDLR-group. However, probands with tendon xanthomas suffered more frequently from CVD below the age of 65 years than probands without tendon xanthomas (26.9% vs.
5.8%; p<0.05). These findings are in concordance with other studies, where patients with tendon xanthomas had higher risk of CVD (Oosterveer et al. 2009; Civeira et al. 2005 ).
The similar clinical manifestation of CVD could be the result of other risk factors than LDL-C levels like smoking, obesity, diabetes, other lipoprotein phenotypes or involvement of other gene variants related to lipid metabolism (data not available). Selection bias cannot be also excluded.
The APOB-/LDLR-group of probands had significantly higher age than positive APOB+ and LDLR+ patients. However, we cannot exclude that hypercholesterolemia in a substantial proportion of APOB-/LDLR-subjects is in fact related to polygenic background and therefore, their phenotype could be manifested in later age compared to monogenic subjects, where high cholesterol is evident from birth. Similar finding was observed in a Czech FH population (Tichy et al. 2012 ).
Moreover, the phenotype of the compound heterozygous patient was less severe than the phenotype of patients with LDLR-negative homozygous mutations. This finding is consistent with the observation form other studies (Cuchel et al. 2014 ).
Strengths and Limitations.
Strength of this study is based on the participation of several specialized outpatient departments (including several pediatric centers) from several parts of Slovakia and the complex DNA analysis of whole LDLR gene. The limitation of our study could be relatively small number of participants according to the estimated FH prevalence.
Implication for clinicians.
Knowledge of the etiology of hypercholesterolemia is very important also from the perspective of clinical medicine. Genetic confirmation of FH in proband simplifies the diagnostic process in proband's family and defines the risk of inheriting FH for the offspring. Confirmation of the FH etiology is particularly important in children, as patients with mutation, severe phenotype and family history of premature CVD, should be medically treated already in childhood or adolescence.
FH criteria used in our study were modified from van Aalst-Cohen, which are similar to Simon Broome criteria, however they are using stricter TC and LDL-C levels adjusted for age and gender. We have also modified the criteria due to relatively low availability and reliability of clinical information from first degree relatives. We are aware that this can lead to lower sensitivity, however, 43.8% detection rate of a genetic defect in our study is similar to other populations (Tichy et al. 2012; Palacios et al. 2012) .
Conclusions
This is the first study assessing the molecular genetic background of autosomal dominant hypercholesterolemia due to LDLR gene mutations, including the first report of genetically confirmed compound heterozygote in Slovakia. The broad mutational spectrum detected in LDLR gene points to the importance of sequencing the whole LDLR gene in patients with a strong clinical suspicion of FH.
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